KyungDong Pharm home
Prescription Medicines

Starizin Tab.

Product Category
Third generation antihistamines
Active Ingredients
Levocetirizine hydrochloride
Appearance
A white or pale yellow, oval, film-coated tablet.
Reimbursement Code
648102470
View Regulatory Information on the MFDS Portal ↗
1. Composition and Strength : 1 tablet
- Active ingredient: Levocetirizine hydrochloride (USP)----5mg
- Additives (animal-derived ingredients): Lactose hydrate (cow, milk)
- Other additives: Microcrystalline cellulose, titanium oxide, magnesium stearate, calcium carboxymethyl cellulose, colloidal silicon oxide, polyethylene glycol 400, hypromellose 2910

2. Effectiveness
Relieve symptoms of the following diseases
1. Seasonal allergic rhinitis or perennial allergic rhinitis (including persistent allergic rhinitis)
2. Chronic idiopathic urticaria
3. Dermatitis and eczema accompanied by itching (combined use with hydrocortisone topical medication)

3. Dosage and dosage
Adults and children over 6 years of age: Take 1 tablet (5 mg as levocetirizine hydrochloride), orally, once a day, regardless of meal. Increase or decrease appropriately depending on age and symptoms.
For patients with renal impairment, the dose is adjusted according to renal function (glomerular filtration rate (eGFR)).

※ Please check the attached document for details.

4. Precautions for use
1. Do not administer to the following patients:
1) Patients with or history of hypersensitivity to the ingredients of this drug and hydroxyzine or piperazine derivatives
2) Patients with end-stage renal disease (glomerular filtration rate (eGFR) < 15mL/min), patients receiving hemodialysis
3) This drug should not be administered to infants under 1 year of age, and liquid, not tablets, should be administered to infants under 6 years of age.
4) Since this drug contains lactose in the tablet, this drug should not be administered to patients with genetic problems such as galactose intolerance, Lapp lactose deficiency, or glucose-galactose malabsorption. (Limited to products containing lactose)

2. Administer with caution to the following patients:
1) Patients with renal impairment (high blood levels may persist.)
2) Patients with liver failure (high blood levels may persist.)
3) Elderly people (high blood levels may persist)

3. Adverse reactions
1) Mental nervous system: Drowsiness, sometimes weariness, headache, paralysis, nervousness, and in rare cases, mild and temporary drowsiness, fatigue, dizziness, heaviness, and excitement may occur.
2) Digestive system: Occasionally dry mouth, dry lips, nausea, loss of appetite, stomach discomfort, indigestion, abdominal pain, stomach pain, abdominal discomfort, rarely vomiting, gastrointestinal disorder, diarrhea, cheilitis, and abnormal taste may occur.
3) Circulatory system: In rare cases, tachycardia, arrhythmia, increased blood pressure, and sometimes palpitations may occur.
4) Blood system: Vasculitis, sometimes decreased leukocytes, decreased neutrophils, increased lymphocytosis, increased eosinophilia, rarely increased mononucleocytes, increased thrombocytopenia, decreased thrombocytopenia.
5) Hypersensitivity: Sensitivity to light, anaphylactic shock, sometimes edema, and rarely rash, itching, and angioedema may occur.
6) Eyes: In rare cases, blurred vision, conjunctival injection, and eye movement seizures may occur.
7) Liver: Occasionally, elevations of AST, ALT, Al-P, and total bilirubin may occur.
8) Kidney: Sometimes BUN elevation, diabetes, and urinary occult blood may occur.
9) Others: Pharyngitis, cough, epistaxis, bronchospasm, hearing abnormalities, visual abnormalities, sometimes chest pain, rarely menstrual irregularities, and tinnitus may occur.
10) As a result of clinical trials on children aged 1 to 6 years, the most common adverse reactions were fever, diarrhea, vomiting, and otitis media.
11) After marketing, aggression, hallucinations, depression, convulsions, paresthesia, difficulty breathing, hives, fixed drug rash, visual impairment, hepatitis, muscle pain, joint pain, weight gain, increased appetite, insomnia, suicidal ideation, dizziness, syncope, tremor, taste abnormality, urinary disorder, urine retention, edema, and nightmares were additionally reported.
12) After discontinuation of levocetirizine, itching and headache were reported in some patients.
13) Domestic post-marketing survey results
A. As a result of a post-marketing survey conducted on 1866 patients (tablets: 1701, liquid: 165) over 4 years for re-examination in Korea, the incidence of adverse events was 1.13% (21/1866, 25 cases). The main adverse events were drowsiness at 0.27% (5 people/1866 people), sedation at 0.21% (4 people/1866 people), and dizziness at 0.11% (2 people/1866 people). Among these, the rate of adverse drug reactions for which a causal relationship with the drug cannot be ruled out was reported to be 0.64% (12 people/1866 people, 12 cases), including drowsiness 0.27% (5 people/1866 people), sedation 0.21% (4 people/1866 people), dizziness 0.11% (2 people/1866 people), and headache. It was 0.05% (1 person/1866 people). Serious adverse events were compression fractures and pneumonia at 0.05% each (1 person/1866 cases, 1 patient), regardless of the causal relationship with the drug, and one case each of unexpected adverse events was reported, regardless of the causal relationship with the drug, including stomatitis, phlegm abnormalities, postnasal drip, difficulty breathing, paresthesia, high blood pressure, compression fractures, and pneumonia.
B. During the re-examination period, a total of 8 cases of unexpected adverse drug reactions reported through voluntary reports, clinical trials, and literature information were reported: 2 cases of muscle pain, 1 case of dilated pupils, 1 case of acne, 1 case of hyperglycemia, 1 case of hives, 1 case of abdominal distension, and 1 case of weight gain.

4. General precautions
1) Drowsiness, fatigue, and asthenia may occur after taking this medicine, so you should be more careful when performing tasks that require alertness, such as driving or operating machinery.
2) Avoid taking this drug with alcohol or antidepressants as it may reduce alertness or further deteriorate central nervous system function.
3) Because levocetirizine may increase the risk of urinary retention, caution should be exercised when administering it to patients with predisposing factors for urinary retention (e.g., spinal cord disorder, enlarged prostate).
4) Epilepsy may worsen after taking this drug, so patients with epilepsy or those at risk of convulsions should be cautious.

5. Interaction
1) As with other antihistamines, do not co-administer with excessive amounts of alcohol.
2) Cetirizine, which is a racemate (optical isomer), does not appear to increase the effects of alcohol (0.5 g/L blood level), but co-administration of levocetirizine with alcohol or other CNS depressants may further reduce alertness and cause performance impairment.
3) There is no study analyzing the interaction with levocetirizine, but there is a study analyzing the interaction with the isomer cetirizine, but there was no interaction with antipyrine, pseudoephedrine, erythromycin, azithromycin, ketoconazole, and cimetidine. A multidose trial with theophylline (400 mg/day) showed a mild (16%) reduction in cetirizine clearance.
4) Ritonavir increased the plasma AUC by 42% with an increase in the half-life (53%) and a decrease in clearance (29%) of cetirizine. The pharmacokinetics of ritonavir were slightly altered (11% reduction) due to co-administration with cetirizine.
5) When taken with food, the absorption rate decreases, but the total amount absorbed does not decrease.

6. Administration to pregnant, lactating, and fertile women
1) Pregnant women
From approximately 300 limited, prospective data collected in pregnant women, no clear evidence of teratogenic or fetal/neonatal toxicity was reported with levocetirizine. Animal studies have not shown direct or indirect harmful effects with respect to pregnancy, embryonic/fetal development, parturition or postnatal development. Caution is required when prescribing to pregnant women.
2) Nursing mothers
There are no data on whether this drug is excreted in breast milk, but since cetirizine is excreted in breast milk, the same is expected for levocetirizine. Because adverse reactions associated with this drug may be observed in breastfed infants, caution is required when prescribing this drug to breastfeeding women.
3) Fertility
Clinical and animal studies have not been conducted on the effect of this drug on fertility.

7. Administration to children
1) The recommended dose for children under 12 years of age was established by comparing the systemic exposure level and safety profile of this drug in adult and pediatric patients.
2) Do not administer to infants under 1 year of age due to limited experience with use.

8. Administration to elderly people
This drug is mainly excreted through the kidneys, so in elderly patients with reduced renal function, excessive blood concentration may persist. Therefore, start administration with caution at a low dose, and if abnormalities are recognized, reduce the dose or stop taking the drug and take appropriate measures.

9. Effect on clinical test values
Since this drug inhibits the intradermal reaction to allergens, it is advisable not to administer this drug 3-5 days before conducting an allergen intradermal reaction test.

10. Treatment in case of overdose
1) In adults, drowsiness appears upon overdose, and in children, drowsiness appears preceded by agitation and restlessness.
2) Since there is no special antidote for this drug, provide symptomatic or supportive treatment in case of overdose. In case of short-term overdose, perform gastric lavage.
3) This drug is not effectively removed by hemodialysis.

11. Pharmaceutical equivalence test information
The test drug Allerin tablets (levocetirizine hydrochloride) [Genuone Science Co., Ltd.] and the reference drug Cijal tablets 5 mg (levocetirizine hydrochloride) [Korea UCB Pharmaceuticals Co., Ltd.] were administered single-time orally on an empty stomach to healthy adults in a 2×2 cross-over study. As a result of measuring levocetirizine in the blood of 29 people, comparative evaluation values (AUCt, Cmax) were obtained. When log transformed and subjected to statistical processing, the 90% confidence interval of the mean difference was within log 0.8 to log 1.25, proving biological equivalence.
* Table: refer to manual

5. How to save
Store in a light-proof, airtight container at room temperature (1~30℃)

6. Packaging unit
30 tablets/bottle, 100 tablets/bottle

7. Period of use
24 months from date of manufacture

Product Updates

Total 3items

No.Product NameDetailsDate of ChangeDownload
3Starizin Tab.Precautions for use2020.06.11PDFPermit change plan (Stari petition).pdf
2Starizin Tab.Stari Soothing (Precautions for use)2015.07.15HWPLevocetirizine hydrochloride_single oral tablet_unified adjustment plan.hwp
1Starizin Tab.Stari Soothing (Precautions for use)2010.04.29HWP9. Order for change in permit (Starri Jinjeong) (2010.04.29).hwp